Elsevier

Nitric Oxide

Volume 5, Issue 2, April 2001, Pages 88-97
Nitric Oxide

Minireview
Nitric Oxide and Atherosclerosis

https://doi.org/10.1006/niox.2001.0337Get rights and content

Abstract

Endothelial dysfunction has been shown in a wide range of vascular desorders including atherosclerosis and related diseases. Here, we examine and address the complex relationship among nitric oxide (NO)-mediated pathways and atherogenesis. In view of the numerous pathophysiological actions of NO, abnormalities could potentially occur at many sites: (a) impairment of membrane receptors in the arterial wall that interact with agonists or physiological stimuli capable of generating NO; (b) reduced concentrations or impaired utilization of l-arginine; (c) reduction in concentration or activity both of inducible and endothelial NO synthase; (d) impaired release of NO from the atherosclerotic damaged endothelium; (e) impaired NO diffusion from endothelium to vascular smooth muscle cells followed by decreased sensitivity to its vasodilator action; (f) local enhanced degradation of NO by increased generation of free radicals and/or oxidation-sensitive mechanisms; and (g) impaired interaction of NO with guanylate cyclase and consequent limitation of cyclic GMP production. Therefore, one target for new drugs should be the preservation or restoration of NO-mediated signaling pathways in arteries. Such novel therapeutic strategies may include administration of l-arginine/antioxidants and gene-transfer approaches.

References (71)

  • D. Behr et al.

    Distribution and prevalence of inducible nitric oxide synthase in atherosclerotic vessels of long-term cholesterol-fed rabbit

    Atherosclerosis

    (1999)
  • F.G. Fowkes et al.

    Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh Artery Study

    Atherosclerosis

    (2000)
  • J.L. Witztum

    The oxidation hypothesis of atherosclerosis

    Lancet

    (1994)
  • C. Napoli et al.

    Influence of maternal hypercholesterolemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study

    Lancet

    (1999)
  • F. de Nigris et al.

    Modulation by α- and γ-tocopherol of apoptotic signaling induced by oxidized low-density lipoprotein in human coronary smooth muscle cells

    Biochem. Pharmacol.

    (2000)
  • Y. Rikitake et al.

    Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells

    Atherosclerosis

    (1998)
  • P. Del Soldato et al.

    NO-aspirins, a class of new-inflammatory and anti-thrombotic agents

    Trends Pharmacol. Sci.

    (1999)
  • A. Uittenbogaard et al.

    High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae

    J. Biol. Chem.

    (2000)
  • R.D. Rudic et al.

    Nitric oxide in endothelial dysfunction and vascular remodeling: Clinical correlates and experimental links

    Am. J. Hum. Genet.

    (1999)
  • R.H. Boger et al.

    Dietary l-arginine and alpha-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms

    Atherosclerosis

    (1998)
  • W.A. Pryor

    Vitamin E and heart disease: Basic science to clinical intervention trials

    Free Radic. Biol. Med.

    (2000)
  • W.G. Christen et al.

    Design of Physicians' Health Study II—a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials

    Ann. Epidemiol.

    (2000)
  • L.J. Ignarro et al.

    Nitric oxide as a signaling molecule in the vascular system: An overview

    J. Cardiovasc. Pharmacol.

    (1999)
  • H. Drexler

    Nitric oxide and coronary endothelial dysfunction in humans

    Cardiovasc. Res.

    (1999)
  • J.P. Cooke

    Is atherosclerosis an arginine deficiency disease?

    J. Invest. Med.

    (1998)
  • P.L. Ludmer et al.

    Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries

    N. Engl. J. Med.

    (1986)
  • A.M. Zeiher et al.

    Endothelial dysfunction of coronary microvasculature is associated with impaired coronary blood flow regulation in patient with early atherosclerosis

    Circulation

    (1991)
  • K. Egashira et al.

    Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

    Circulation

    (1994)
  • M.A. Creager et al.

    Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans

    J. Clin. Invest.

    (1990)
  • Y. Ohara et al.

    Hypercholesterolemia increases in endothelial superoxide anion production

    J. Clin. Invest.

    (1993)
  • L.D. Buttery et al.

    Inducible NO synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite

    Lab. Invest.

    (1996)
  • M.A. Creager et al.

    L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans

    J. Clin. Invest.

    (1992)
  • A. Lerman et al.

    Long-term l-arginine supplementation improves small-vessel coronary endothelial function in humans

    Circulation

    (1998)
  • A. Blum et al.

    Oral l-arginine in patients with coronary artery disease on medical management

    Circulation

    (2000)
  • H. Miyazaki et al.

    Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis

    Circulation

    (1999)
  • Cited by (0)

    1

    To whom correspondence and reprint requests should be addressed. E-mail: [email protected] or [email protected].

    View full text